chartexchange

INAB
IN8bio, Inc. Common Stock
stockNASDAQ

At CloseNov 18, 2026 10:27:52 AM EST
0.79USD-3.646%(-0.03)30,768
Pre-marketNov 18, 2026 8:43:30 AM EST
0.801USD-2.317%(-0.019)
After-hoursNov 18, 2026 4:00:30 PM EST
0.78USD-1.278%(-0.01)
Loading…
Loading…
Healthcare
Biotechnology
HQ
New York, NY, USA
Previous Close
$0.82
Beta
1.40
52-Week High
$2.73 2026-01-16
52-Week Low
$0.72 2026-11-16
SMA 50
$1.08
SMA 200
$1.37
Avg. Vol 10D
542,485
Avg. Vol 30D
206,193
Avg. Vol 90D
107,733
Relative Vol
0.15
8.13M
4.4700%
607
Jun 6, 2025 · 1-for-30 (reverse)
INAB Profile

in8bio, inc. ("in8bio") is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.

INAB Performance
PeriodPriceDateChangeBeta
1W0.822026-11-12-4.86%-1.476
1M1.092026-10-19-28.40%1.645
3M1.202026-08-19-34.97%1.412
6M1.452026-05-19-46.18%1.185
1Y1.622025-11-19-51.83%1.402
2Y9.512024-11-19-91.79%—
5Y204.002021-11-19-99.62%0.496
INAB Stock Summary

IN8bio, Inc. Common Stock (NASDAQ:INAB) stock price today is $0.78, and today's volume is 30,768. INAB is down 4.829% today. The 30 day average volume is 206,193. INAB market cap is $8.43M with 10.81M shares outstanding.